| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| State of incorporation | NV | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| Fiscal year end (MMDD) | 0630 | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| Business address | MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | 2026-11-22 01:07 UTC | Report an error |
|---|
| Revenue (fiscal year ended 2026-06-30) | $1,016,000 | 2026-06-30 | 10-K, XBRL Revenues | 2026-11-22 01:07 UTC | Report an error |
|---|
| Net income (loss) (fiscal year ended 2026-06-30) | $-23,821,000 | 2026-06-30 | 10-K, XBRL NetIncomeLoss | 2026-11-22 01:07 UTC | Report an error |
|---|
| Total assets (at 2026-06-30) | $24,878,000 | 2026-06-30 | 10-K, XBRL Assets | 2026-11-22 01:07 UTC | Report an error |
|---|
| Stockholders' equity (at 2026-06-30) | $-23,036,000 | 2026-06-30 | 10-K, XBRL StockholdersEquity | 2026-11-22 01:07 UTC | Report an error |
|---|
| Cash and cash equivalents (at 2026-06-30) | $3,529,000 | 2026-06-30 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | 2026-11-22 01:07 UTC | Report an error |
|---|
| Operating cash flow (fiscal year ended 2026-06-30) | $-19,588,000 | 2026-06-30 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | 2026-11-22 01:07 UTC | Report an error |
|---|
| Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30) | $633,000 | 2026-06-30 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | 2026-11-22 01:07 UTC | Report an error |
|---|
| Operating lease liabilities (at 2026-06-30) | $7,483,000 | 2026-06-30 | 10-K, XBRL OperatingLeaseLiability | 2026-11-22 01:07 UTC | Report an error |
|---|
| Form D total offering amount (D filed 2026-09-04) | $3,677,751 | 2026-09-04 | D | 2026-11-22 01:07 UTC | Report an error |
|---|
| Form D total amount sold (D filed 2026-09-04) | $3,677,751 | 2026-09-04 | D | 2026-11-22 01:07 UTC | Report an error |
|---|
| Form D industry group | Biotechnology | 2026-09-04 | D | 2026-11-22 01:07 UTC | Report an error |
|---|
| Form D revenue range | Decline to Disclose | 2026-09-04 | D | 2026-11-22 01:07 UTC | Report an error |
|---|
| Form D date of first sale | 2026-08-28 | 2026-09-04 | D | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 1.01, Entry into a Material Definitive (filed 2026-10-30) | Agreement. ZEO Partnership Agreement On October 26, 2026, Pluri Inc. (“Pluri” or the “Company”) entered into a Partnership Agreement (the “Agreement”) with ZEO ScientifiX, Inc. (“ZEO”) pursuant to which, at the closing of the transactions contemplated under the Agreement the Company shall grant ZEO an exclusive license solely to manufacture and commercialize its regenerative medicine product portfolio (except where such products are intended for aesthetics, skin care, cosmetic, or veterinary applications, in which case ZEO may only commercialize such products) in the United States (the “License”), which may also be expanded to Latin America under the terms of the Agreement. Pursuant to the… | 2026-10-30 | SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 3.02, Unregistered Sales of Equity (filed 2026-10-30) | Securities. The information set forth under the subheadings “ZEO Partnership Agreement” and “Securities Purchase Agreements” in | 2026-10-30 | SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 1.01, of this Current Report on Form 8-K are incorporated into this Item 3.02 by reference (filed 2026-10-30) | The ZEO Transaction Securities described under the subheading “ZEO Partnership Agreement” in Item 1.01 above were offered and agreed to be sold in reliance upon exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. The offer and sale of the Securities did not involve any general solicitation or general advertising. The Securities have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration… | 2026-10-30 | SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 8.01, Other Events (filed 2026-10-30) | As previously disclosed, the Company, together with its subsidiaries, Pluri Biotech Ltd., incorporated under the laws of Israel, and Pluristem GmbH, incorporated under the laws of Germany (the “Subsidiaries”), entered into a finance agreement with the European Investment Bank (“EIB”) providing for up to €50 million in funding, of which only the first tranche of €20 million was disbursed in June 2021, and such amount bears interest at 4% per annum, and was scheduled to become repayable on June 1, 2026 (as amended by the Consent and Amendment Letter No, 1, dated as of February 10, 2025, the “Loan”). The Company also previously disclosed that on April 21, 2026, the Company received notice from… | 2026-10-30 | SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-20) | As previously disclosed, on June 14, 2026, Pluri Inc. (the “Company”) entered into an advance subscription agreement with Chutzpah Holdings LP (the “Purchaser”), a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor, the Company’s largest existing shareholder and the chairman of the board of directors of the Company (the “Board”), pursuant to which the Purchaser paid the Company $1,250,000 on June 16, 2026 as an advance payment to be credited against the purchase price payable by the Purchaser for securities to be purchased in a future financing, subject to the approval of the Board. On October 19, 2026, following approval by the Board, the Company and the… | 2026-10-20 | SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-20) | Pursuant to the Purchase Agreement described in | 2026-10-20 | SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 1.01, above, which description is incorporated into this Item 3.02 by reference, the Securities were issued in reliance upon the exemption (filed 2026-10-20) | from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) and Rule 903 of Regulation S promulgated thereunder. The sale of the Securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Securities have not been registered under the Securities Act or any state securities laws and such securities may not be offered or sold in the United States absent registration, or an exemption from registration, under the Securities Act and any applicable state securities law. 1 | 2026-10-20 | SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-28) | On August 26, 2026, Pluri Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Registered Direct Offering”) registered under the Securities Act of 1933, as amended (the “Securities Act”), an aggregate of (i) 1,200,000 (the “Shares”) of the Company’s common shares (“Common Shares”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,028,940 Common Shares (such shares issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”, and together with the Shares and… | 2026-08-28 | SEC EDGAR 8-K 0001213900-26-094638 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-08-28) | Pursuant to the Concurrent Private Placement described in Item 1.01 above, which description is incorporated into this Item 3.02 by reference, the Common Warrants (including the Common Stock issuable upon exercise of the Common Warrants) (collectively, the “Private Securities”) were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act and Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Private Securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Private Securities have not been… | 2026-08-28 | SEC EDGAR 8-K 0001213900-26-094638 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| 8-K Item 8.01, Other Events (filed 2026-08-17) | On August 12, 2026, Ever After Foods Ltd. (“EAF”), an indirect majority-owned subsidiary of Pluri Inc. (the “Company”), entered into a share purchase agreement (the “Share Purchase Agreement”) with Fishway BV (“Fishway”) and the holders of certain securities of Fishway as specified in the Share Purchase Agreement (the “Sellers”). Pursuant to the Share Purchase Agreement, and subject to the satisfaction or waiver of customary closing conditions, EAF agreed to acquire all of the outstanding share capital of Fishway in exchange for the issuance of EAF’s ordinary shares to the Sellers (the “Transaction”). The Transaction is intended to support EAF’s European strategy through Fishway’s Belgian… | 2026-08-17 | SEC EDGAR 8-K 0001213900-26-090738 (text as filed, excerpt) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #1 (13F as filed): RENAISSANCE TECHNOLOGIES LLC | $38,297 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #2 (13F as filed): EverSource Wealth Advisors, LLC | $4,180 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #3 (13F as filed): UBS Group AG | $4,009 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #4 (13F as filed): SIMA Wealth Partners, LLC | $732 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #5 (13F as filed): CITIGROUP INC | $393 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #6 (13F as filed): WELLS FARGO & COMPANY/MN | $386 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #7 (13F as filed): JPMORGAN CHASE & CO | $269 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #8 (13F as filed): SBI Securities Co., Ltd. | $203 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #9 (13F as filed): TD Waterhouse Canada Inc. | $198 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|
| Largest institutional holder #10 (13F as filed): Activest Wealth Management | $177 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-22 01:07 UTC | Report an error |
|---|